読み込み中
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
前日終値
$1.37
+$0.05 · +3.79%
市場前
$1.4197
+$0.0497 · +3.63%
10月9日 5:32 ET
日中の時刻はETです。市場データは遅延する場合があります。
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
日中レンジ
現在 $1.37
52週レンジ
現在 $1.37
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
27
割高
センチメント
44
まちまち
リスク
63
高リスク
モメンタム
41
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.
日中レンジ
現在 $1.37
52週レンジ
現在 $1.37
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上原価 | 140.9万 USD | — | — | — | — |
| 粗利益 | −140.9万 USD | — | — | — | — |
| 研究開発 | 6197.9万 USD | 1.18億 USD | 1.03億 USD | 6271.3万 USD | 2799.6万 USD |
| 販売・一般管理 | 1932.8万 USD | 2598.5万 USD | 2358.9万 USD | 2092.1万 USD | 1367.1万 USD |
| 営業費用 | 7989.8万 USD | 1.44億 USD | 1.26億 USD | 8363.4万 USD | 4166.7万 USD |
| 受取利息 | 185.8万 USD | 564.4万 USD | 888万 USD | 180.6万 USD | 10万 USD |
| 減価償却費と償却費 | 140.9万 USD | 174.8万 USD | 151.5万 USD | 69.1万 USD | 24.9万 USD |
| 営業利益 | −8130.7万 USD | −1.44億 USD | −1.26億 USD | −8363.4万 USD | −4166.7万 USD |
| 純利益 | −6179.7万 USD | −1.38億 USD | −1.17億 USD | −8182.8万 USD | −4156.7万 USD |
会社概要が更新されました 2026年10月9日.
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI356.51万0.00%2.3兆 USD0.03%$379.56-0.39%
Vanguard Extended Market ETFVXF106.54万0.00%954億 USD0.05%$233.13-0.15%
iShares Micro-Cap ETFIWC28.89万0.02%13.19億 USD0.60%$182.79-0.31%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM11万0.10%1.17億 USD0.73%$15.90-0.44%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
